Veracyte shares surge 27.46% intraday as Q3 earnings, revenue exceed estimates and 2025 guidance raised.

Veracyte (VCYT) surged 27.46% intraday following a strong Q3 earnings report that exceeded expectations. The company reported earnings per share of 51 cents, surpassing the 32-cent forecast, and revenue of $131.9 million, beating the $124.85 million estimate. Upwardly revised 2025 revenue guidance to $506–$510 million, coupled with new coverage from Freedom Capital—a buy rating and $45 price target—fueled optimism. Recent advancements in diagnostic tools like Afirma GRID for thyroid cancer also highlighted growth potential, driving investor enthusiasm. While a $27 million one-off loss and mixed profitability metrics were noted, the earnings outperformance and revised guidance were the primary catalysts for the intraday rally.